|
1.
|
Quantification of trace $^{227}$Ac and other radionuclidic impurities in mass-separated $^{225}$Ac samples produced at CERN-MEDICIS
/ Johnson, Jake D (Leuven U.) ; Bernerd, Cyril (Leuven U. ; CERN) ; Bruchertseifer, Frank (Unlisted, DE) ; Cocolios, Thomas E (Leuven U.) ; Deseyn, Marie (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heines, Michael (Leuven U.) ; Keppens, Max (Leuven U.) ; Lambert, Laura (CERN) ; Meurrens, Nathan (Leuven U.) et al.
$^{225}$Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover $^{225}$Ac from hundreds of co-produced spallation and fission products. [...]
2025 - 14 p.
- Published in : Sci. Rep. 15 (2025) 23563
Fulltext: PDF;
|
|
|
2.
|
Novel radionuclides: demand, production and distribution for translational research in Europe
/ Radzina, Maija (CERN ; Latvia U.) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (CERN ; Latvia U.) ; Pajuste, Elina (Latvia U.) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Proskurins, Jevgenijs (Unlisted, LV) ; Kalnina, Patricija (Latvia U.) ; Zabolockis, Rudolfs Janis (Latvia U.) ; Palskis, Kristaps (CERN ; Latvia U.) et al.
Background: In the feld of medical and scientifc research, radionuclides are used to investigate various physiological and pathological processes. PRISMAP - the European medical radionuclide programme was created to bring together production facilities including intense neutron sources, an isotope mass separation facility, highpower accelerators, biomedical research institutes, and hospitals to support medical research [...]
2024 - 16 p.
- Published in : EJNMMI Radiopharmacy and Chemistry 9 (2024) 85
Published version: PDF;
|
|
|
3.
|
|
|
4.
|
Target Development towards First Production of High-Molar- Activity $^{44g}$Sc and $^{47}$Sc by Mass Separation at CERN-MEDICIS
/ Mamis, Edgars (CERN ; Latvia U.) ; Duchemin, Charlotte (CERN) ; Berlin, Valentina (CERN) ; Bernerd, Cyril (CERN) ; Bovigny, Mathieu (CERN) ; Chevallay, Eric (CERN) ; Crepieux, Bernard (CERN) ; Gadelshin, Vadim Maratovich (Mainz U., Inst. Phys.) ; Heinke, Reinhard (CERN) ; Hernandez, Ronaldo Mendez (CERN ; Havana, ISCTN) et al.
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. [...]
2024 - 28 p.
- Published in : Pharmaceuticals 17 (2024) 390
Fulltext: PDF;
|
|
|
5.
|
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
/ Radzina, Maija (Latvia U. ; CERN) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (Latvia U. ; CERN) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Pajuste, Elina (Latvia U.) ; Kalnina, Marika (Unlisted) ; Palskis, Kristaps (CERN ; Riga Tech. U.) ; Sawitzki, Zoe (Leuven U.) ; Talip, Zeynep (PSI, Villigen) et al.
Background
In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.
Main body
A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. [...]
2023 - 16 p.
- Published in : EJNMMI Radiopharm. Chem. 8 (2023) 27
Fulltext: PDF;
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
/ Vermeulen, Koen (SCK-CEN, Mol) ; Van de Voorde, Michiel (SCK-CEN, Mol) ; Segers, Charlotte (SCK-CEN, Mol) ; Coolkens, Amelie (SCK-CEN, Mol) ; Pérez, Sunay Rodriguez (SCK-CEN, Mol) ; Daems, Noami (SCK-CEN, Mol) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Crabbé, Melissa (SCK-CEN, Mol) ; Opsomer, Tomas (SCK-CEN, Mol) ; Vargas, Clarita Saldarriaga (SCK-CEN, Mol) et al.
Samarium-153 is a promising theranostic radionuclide, but low molar activities (Am) resulting from its current production route render it unsuitable for targeted radionuclide therapy (TRNT). Recent efforts combining neutron activation of $^{152}$Sm in the SCK CEN BR2 reactor with mass separation at CERN/MEDICIS yielded high-Am $^{153}$Sm. [...]
2022 - 15 p.
- Published in : Pharmaceutics 14 (2022) 2566
Fulltext: PDF;
|
|
|
9.
|
|
|
10.
|
Resonant laser ionization and mass separation of $^{225}$Ac
/ Johnson, Jake D (Leuven U.) ; Heines, Michael (Leuven U.) ; Bruchertseifer, Frank (Geel, JRC) ; Chevallay, Eric (CERN) ; Cocolios, Thomas E (Leuven U.) ; Dockx, Kristof (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heinitz, Stephan (SCK-CEN, Mol) ; Heinke, Reinhard (Leuven U. ; CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) et al.
$^{225}$Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing $^{225}$Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure $^{225}$Ac itself. [...]
2023 - 11 p.
- Published in : Sci. Rep. 13 (2023) 1347
Fulltext: PDF;
|
|
email alert
or subscribe to the 
RSS feed.